{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-298869","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.963277+00:00","generated_at":"2026-06-21T08:59:28.955831+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Equillium receives $26M upfront from Ono for itolizumab option; up to $138.5M in milestones","bullets":["Upfront payment of $26.0M (¥3.5B) non-refundable; option exercise payment of $37.1M (¥5.0B) if exercised.","Eligible for up to $101.4M development milestones, plus exercise payment, total up to ~$138.5M.","Ono will fully fund Equillium's R&D for itolizumab quarterly from July 1, 2022 through option period.","Option expires 3 months after topline EQUALISE (lupus nephritis) and interim EQUATOR (aGVHD) data.","Equillium expects funding into 2025; advancing wholly-owned pipeline (EQ101, EQ102)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-298869","json":"https://secwatch.observer/filing/0001193125-22-298869.json","markdown":"https://secwatch.observer/filing/0001193125-22-298869.md","text":"https://secwatch.observer/filing/0001193125-22-298869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312522298869/0001193125-22-298869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312522298869/d348600d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:59:28.955831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf87166b5ea36155ab5d78a22e8e37bb1eae03a0","claim":"Equillium, Inc. entered into Purchase Agreement with Ono Pharmaceutical Co., Ltd. valued at JPY 3.5 billion (effective 2022-12-05).","evidence_excerpt":"On December 5, 2022, Equillium, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ono Pharmaceutical Co., Ltd. a Japan kabushiki kaisha (“Ono”), pursuant which the Company granted Ono the exclusive right, but not the obligation, to acquire the Company’s rights to itolizumab, a first-in-class monoclonal antibody targeting CD6 (the “Option”). In exchange for the Option, Ono will pay the Company a one-time, non-refundable upfront payment of an amount equal to JPY 3.5 billion, or approximately $26.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000119312522298869/0001193125-22-298869-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Ono Pharmaceutical Co., Ltd."},{"label":"Value","value":"JPY 3.5 billion"},{"label":"Effective","value":"2022-12-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}